Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDIŽ (inotersen) BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the NEURO-TTR open-label extension study and the clinical impact of TEGSEDI on patients living with hereditary transthyretin amyloidosis (hATTR) will be presented at the 5th European Academy of Neurology Annual Congress (EAN) in Oslo, Norway, June 29-July 2, 2019. Ionis Logo Oral Presentation: Monday, July 1, 2019 5:15 PM - 5:30 PM UTC Long-Term Efficacy and...
|